title: Prevention of Transfusion-Transmitted Cytomegalovirus Infections: Which is the Optimal Strategy?
abstract: Traditionally, leukoreduction and selection of blood products from seronegative donors have been used as alternative strategies to reduce the risk of transfusion-transmitted cytomegalovirus infections (TT-CMV) in atrisk patients. After the introduction of universal leukoreduction for red blood cell and platelet concentrates in Germany, a controversy evolved as to whether the additional selection of blood products from seronegative donors would reduce or even increase the risk of TT-CMV. This review summarizes the current knowledge about CMV infections in blood donors and the implications of this information on the effect of potential transfusion strategies. Even though there are conflicting data about the incidence of TT-CMV remaining after the introduction of leukodepletion, it has been clearly shown that both prevalence and concentration of CMV DNA in peripheral blood are highest in newly seropositive donors. Therefore, avoidance of blood products from these donors is the most important goal of any transfusion strategy. This goal can be reached by: i) selection of blood products from seronegative donors, ii) provision of CMV DNA-negative blood products, or iii) provision of blood from long-term seropositive donors. In cases of suspected TT-CMV, all implicated donors should be investigated carefully to gather further knowledge on which donors confer the lowest risk for TT-CMV.
authors.affiliation: Institute of Transfusion Medicine, University Hospital of Schleswig-Holstein, Lübeck, Germany.
authors.forename: Malte
authors.initials: M
authors.lastname: Ziemann
authors.affiliation: Institute of Transfusion Medicine, University Hospital of Schleswig-Holstein, Lübeck, Germany.
authors.forename: Holger
authors.initials: H
authors.lastname: Hennig
keywords: Blood donor; CMV; Human cytomegalovirus; Transfusion; Transfusion-associated infections